§ Rev. Martin SmythTo ask the Secretary of State for Northern Ireland how many people with haemophilia in Northern Ireland who require factor VIII infusions are being treated with the high-purity monoclonal products; how many are being treated with the intermediate purity concentrates; if he will break the figures down by product manufacturer; if he will break the figures down in terms of the number of units of each product prescribed in the latest year for which data are available; and if he will break down the figures for each health and social services board.
§ Mr. Hanley[holding answer 7 February 1991]: The available information is as follows. In 1989 three patients who were allergic to intermediate purity Factor VIII were treated with 34,210 units of high purity monoclonal products manufactured by Baxter Health Care Ltd. In the same year approximately 100 patients were treated with intermediate purity Factor VIII concentrate manufactured by the Scottish National Blood Transfusion Service (1.6 million units) and by Alphatherapeutic (UK) Ltd. (1.6 575W million units). As treatment for haemophilia patients in Northern Ireland is provided on a regional basis at the Royal Victoria hospital the figures for each health and social services board are not readily available.